About Grail
GRAIL, Inc. (Nasdaq: GRAL) is a healthcare company focused on the early detection of multiple cancers through a single blood draw using its proprietary multi-cancer early detection (MCED) technology. Its flagship product, the Galleri® test, analyzes cell-free DNA methylation patterns in the bloodstream to detect a shared cancer signal across more than 50 cancer types, targeting asymptomatic adults aged 50 and older. The company leverages next-generation sequencing, population-scale clinical studies, and advanced data science to serve physicians and health systems seeking non-invasive cancer screening solutions.
Company details
Funding
Total raised
$2.0B
Last stage
Public
Investors
Founders
Alex Aravanis
Scientist and entrepreneur who co-founded GRAIL alongside Jeff Huber; previously held senior roles at Illumina.
LinkedInRichard (Rick) Klausner
Former Director of the U.S. National Cancer Institute (1995–2001) and former Chief Medical Officer at Illumina. Serial biotech founder (Juno Therapeutics, GRAIL, Altos Labs). MD from Duke Medical School.
Jeff Huber
Former SVP at Google (co-founded Google's life sciences efforts in Google[x]). Founding CEO of GRAIL. Currently Co-Founder & General Partner at Triatomic Capital.
LinkedInMostafa Ronaghi
Former SVP and Chief Technology Officer at Illumina. Co-founder of GRAIL, ParAllele BioScience, NextBio, and Cellanome. PhD from the Royal Institute of Technology, Sweden.
LinkedInWhat happens next.
No applications, no recruiter spam. Just the intro.
Confirm the fit
A few questions to make sure this role is the right shape for you. Two minutes.
I pitch you to the company
I write the intro, send it to the founder, and handle the back-and-forth.
A meeting lands on your calendar
If they’re a yes, I book the chat. You show up — that’s the whole job-hunt.